

# Silvia Crescioli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3309924/publications.pdf>

Version: 2024-02-01

42  
papers

1,623  
citations

361413

20  
h-index

330143

37  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2391  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodies to watch in 2022. <i>MAbs</i> , 2022, 14, 2014296.	5.2	239
2	AllergoOncology: Danger signals in allergology and oncology: AÂEuropean Academy of Allergy and Clinical Immunology (EAACI) Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2594-2617.	5.7	5
3	Innate stimulation of B cells <i>in vivo</i> enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. <i>Clinical and Experimental Immunology</i> , 2022, 207, 84-94.	2.6	4
4	Special Issue "Antibody Engineering for Cancer Immunotherapy". <i>Antibodies</i> , 2022, 11, 29.	2.5	1
5	<i>In vivo</i> trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. <i>Oncolmmunology</i> , 2021, 10, 1966970.	4.6	2
6	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.		0
7	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	2.9	71
8	Utilizing Immunocytokines for Cancer Therapy. <i>Antibodies</i> , 2021, 10, 10.	2.5	24
9	Harnessing the hERG1/Î²1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1338-1349.	4.1	16
10	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
11	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 4290-4304.	0.9	40
12	Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. <i>Cancers</i> , 2021, 13, 4460.	3.7	15
13	<i>In vivo</i> safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. <i>MAbs</i> , 2020, 12, 1685349.	5.2	11
14	Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG1 and IgG4 against the Major Birch Pollen Allergen Bet v 1. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5693.	4.1	3
15	Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). <i>Scientific Reports</i> , 2020, 10, 8869.	3.3	11
16	A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma. <i>Cancers</i> , 2020, 12, 1029.	3.7	22
17	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 622442.	4.8	39
18	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	4.8	177

#	ARTICLE	IF	CITATIONS
19	IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. <i>EBioMedicine</i> , 2019, 43, 67-81.	6.1	49
20	AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1985-1989.	5.7	14
21	In Planta Glycan Engineering and Functional Activities of IgE Antibodies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 242.	4.1	19
22	An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2328-2341.	5.7	24
23	Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1519-1523.e9.	2.9	19
24	Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). <i>Oncolmmunology</i> , 2018, 7, e1395127.	4.6	117
25	AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 328-340.	5.7	54
26	Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5098-5111.	7.0	65
27	Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. <i>Frontiers in Immunology</i> , 2018, 9, 493.	4.8	14
28	Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging. <i>Oncotarget</i> , 2018, 9, 34972-34989.	1.8	19
29	Abstract LB-001: Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer. , 2018, , .		1
30	Anti-Folate Receptor-Î± IgE but not IgG Recruits Macrophages to Attack Tumors via TNFÎ±/MCP-1 Signaling. <i>Cancer Research</i> , 2017, 77, 1127-1141.	0.9	58
31	B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. <i>Oncolmmunology</i> , 2017, 6, e1294296.	4.6	51
32	Recombinant plant-derived human IgE glycoproteomics. <i>Journal of Proteomics</i> , 2017, 161, 81-87.	2.4	16
33	The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. <i>Science Signaling</i> , 2017, 10, .	3.6	49
34	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. <i>Frontiers in Immunology</i> , 2017, 8, 1112.	4.8	17
35	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. <i>Oncotarget</i> , 2017, 8, 78174-78192.	1.8	75
36	Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types. <i>Frontiers in Immunology</i> , 2017, 8, 1911.	4.8	87

#	ARTICLE	IF	CITATIONS
37	IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Scientific Reports, 2016, 6, 29736.	3.3	52
38	IgG4 Characteristics and Functions in Cancer Immunity. Current Allergy and Asthma Reports, 2016, 16, 7.	5.3	76
39	Abstract A116: IgG antibody switching and clonal expansion in melanoma and normal skin microenvironments. , 2016, , .		0
40	Abstract 1324: A translational platform to design antibodies targeting triple negative breast cancer-specific antigens for cancer immunotherapy. , 2015, , .		0
41	VEGF-A clinical significance in gastric cancers: Immunohistochemical analysis of a wide Italian cohort. European Journal of Surgical Oncology, 2014, 40, 1291-1298.	1.0	3
42	hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications. Clinical Cancer Research, 2014, 20, 1502-1512.	7.0	54